Rhythm Biosciences Limited (FRA:0RY)

Market Cap	15.10M
Revenue (ttm)	1.78M
Net Income (ttm)	-2.14M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	n/a
Open	0.0480
Previous Close	0.0500
Day's Range	0.0480 - 0.0480
52-Week Range	0.0270 - 0.0825
Beta	n/a
RSI	45.22
Earnings Date	Aug 29, 2025

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. The company develops ColoSTAT, a blood test for the early detection of colorectal cancer. It also acquired Genetype to expand product offerings. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2017
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0RY

Financial Performance

In 2025, Rhythm Biosciences's revenue was 3.19 million, an increase of 88.85% compared to the previous year's 1.69 million. Losses were -3.83 million, -44.15% less than in 2024.

Financial numbers in AUD